As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
11 Analysts have issued a Dermapharm forecast:
11 Analysts have issued a Dermapharm forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1,160 1,160 |
0%
0%
|
|
| Gross Profit | 772 772 |
3%
3%
|
|
| EBITDA | 305 305 |
0%
0%
|
|
| EBIT (Operating Income) EBIT | 217 217 |
5%
5%
|
|
| Net Profit | 116 116 |
28%
28%
|
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.
| Head office | Germany |
| CEO | Hans-Georg Feldmeier |
| Employees | 3,610 |
| Founded | 1991 |
| Website | ir.dermapharm.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


